MA43960B1 - Triterpénoïdes modifiés en c-3 et c-17 utilisés comme inhibiteurs du vih-1 - Google Patents

Triterpénoïdes modifiés en c-3 et c-17 utilisés comme inhibiteurs du vih-1

Info

Publication number
MA43960B1
MA43960B1 MA43960A MA43960A MA43960B1 MA 43960 B1 MA43960 B1 MA 43960B1 MA 43960 A MA43960 A MA 43960A MA 43960 A MA43960 A MA 43960A MA 43960 B1 MA43960 B1 MA 43960B1
Authority
MA
Morocco
Prior art keywords
hiv
inhibitors
compounds
modified triterpenoids
relates
Prior art date
Application number
MA43960A
Other languages
English (en)
French (fr)
Other versions
MA43960A (fr
Inventor
Sing-Yuen Sit
Yan Chen
Jie Chen
Jacob Swidorski
Brian Lee Venables
Ny Sin
Alicia Regueiro-Ren
Ira B Dicker
Richard A Hartz
Nicholas A Meanwell
Original Assignee
Viiv Healthcare Uk No 5 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viiv Healthcare Uk No 5 Ltd filed Critical Viiv Healthcare Uk No 5 Ltd
Publication of MA43960A publication Critical patent/MA43960A/fr
Publication of MA43960B1 publication Critical patent/MA43960B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J53/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002Carbocyclic rings fused
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C12N9/506Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J63/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008Expansion of ring D by one atom, e.g. D homo steroids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00Systems containing at least three condensed rings
    • C07C2603/02Ortho- or ortho- and peri-condensed systems
    • C07C2603/52Ortho- or ortho- and peri-condensed systems containing five condensed rings
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16211Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
MA43960A 2016-02-04 2017-02-02 Triterpénoïdes modifiés en c-3 et c-17 utilisés comme inhibiteurs du vih-1 MA43960B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662291298P 2016-02-04 2016-02-04
PCT/IB2017/050568 WO2017134596A1 (en) 2016-02-04 2017-02-02 C-3 and c-17 modified triterpenoids as hiv-1 inhibitors

Publications (2)

Publication Number Publication Date
MA43960A MA43960A (fr) 2018-12-12
MA43960B1 true MA43960B1 (fr) 2021-02-26

Family

ID=57995251

Family Applications (2)

Application Number Title Priority Date Filing Date
MA43960A MA43960B1 (fr) 2016-02-04 2017-02-02 Triterpénoïdes modifiés en c-3 et c-17 utilisés comme inhibiteurs du vih-1
MA053358A MA53358A (fr) 2016-02-04 2017-02-02 Triterpénoïdes modifiés en c-3 et c-17 utilisés comme inhibiteurs du vih-1

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA053358A MA53358A (fr) 2016-02-04 2017-02-02 Triterpénoïdes modifiés en c-3 et c-17 utilisés comme inhibiteurs du vih-1

Country Status (39)

Country Link
US (4) US10421774B2 (enExample)
EP (2) EP3831839B1 (enExample)
JP (1) JP6735837B2 (enExample)
KR (1) KR102795662B1 (enExample)
CN (1) CN109153700B (enExample)
AR (1) AR107512A1 (enExample)
AU (1) AU2017215529B2 (enExample)
BR (1) BR112018015629B1 (enExample)
CA (1) CA3013417C (enExample)
CL (1) CL2018002084A1 (enExample)
CO (1) CO2018008157A2 (enExample)
CR (1) CR20180387A (enExample)
CY (1) CY1124353T1 (enExample)
DK (1) DK3411381T3 (enExample)
DO (1) DOP2018000174A (enExample)
EA (1) EA036211B1 (enExample)
ES (2) ES2862325T3 (enExample)
HR (1) HRP20210502T1 (enExample)
HU (1) HUE054337T2 (enExample)
IL (1) IL260741B (enExample)
JO (1) JOP20170029B1 (enExample)
LT (1) LT3411381T (enExample)
MA (2) MA43960B1 (enExample)
MD (1) MD3411381T2 (enExample)
MX (1) MX375118B (enExample)
MY (1) MY199668A (enExample)
PE (1) PE20181355A1 (enExample)
PL (1) PL3411381T3 (enExample)
PT (1) PT3411381T (enExample)
RS (1) RS61746B1 (enExample)
RU (1) RU2716502C2 (enExample)
SG (1) SG11201806388XA (enExample)
SI (1) SI3411381T1 (enExample)
SM (1) SMT202100210T1 (enExample)
TW (1) TWI719126B (enExample)
UA (1) UA123867C2 (enExample)
UY (1) UY37109A (enExample)
WO (1) WO2017134596A1 (enExample)
ZA (1) ZA201805044B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR107512A1 (es) * 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
ES2970042T3 (es) 2018-04-24 2024-05-24 Viiv Healthcare Uk No 5 Ltd Compuestos con actividad inhibidora de la maduración del VIH
JP7703538B2 (ja) 2019-12-09 2025-07-07 ヴィーブ、ヘルスケア、カンパニー カボテグラビルを含んでなる医薬組成物
WO2024089216A1 (en) 2022-10-27 2024-05-02 Syngenta Crop Protection Ag Novel sulfur-containing heteroaryl carboxamide compounds
WO2025037232A1 (en) 2023-08-11 2025-02-20 ViiV Healthcare UK (No.4) Limited Tosylate salt form of a maturation inhibitor for treatment of hiv
AU2024353051A1 (en) 2023-09-27 2026-03-12 ViiV Healthcare UK (No.3) Limited Pharmaceutical compositions
AU2023466962A1 (en) 2023-09-27 2026-03-12 ViiV Healthcare UK (No.3) Limited Pharmaceutical composition of cabotegravir

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5679828A (en) 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7365221B2 (en) 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
GB0301227D0 (en) 2003-01-20 2003-02-19 Keen Group Ltd Seating apparatus
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
BRPI0508854A (pt) 2004-03-17 2007-08-28 Panacos Pharmaceuticals Inc sais farmacêuticos de ácido-3-o-(3',3'-dimetilsuccinil) betulìnico
TW200628161A (en) 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
WO2008115281A2 (en) 2006-10-16 2008-09-25 Myriad Genetics, Inc. Compounds for treating viral infections
CA2714049A1 (en) 2008-02-14 2009-08-20 Virochem Pharma Inc. Novel 17.beta. lupane derivatives
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
FR2956034B1 (fr) 2010-02-09 2012-02-10 Thales Sa Dispositif d'entrainement pour des joueurs de rugby
RS54239B1 (sr) 2010-06-04 2015-12-31 Bristol-Myers Squibb Company C-28 amidi modifikovanih derivata c-3 betulinske kiseline kao inhibitori sazrevanja hiv-a
US8754068B2 (en) 2010-06-04 2014-06-17 Bristol-Myers Squibb Company Modified C-3 betulinic acid derivatives as HIV maturation inhibitors
DE102010017786A1 (de) 2010-07-07 2012-01-12 Continental Reifen Deutschland Gmbh Elastomerprodukt, enthaltend ein linienförmiges, textiles Gebilde zur Verstärkung
HUE026371T2 (en) 2011-01-31 2016-05-30 Bristol Myers Squibb Co C-28 amines from modified C-3 betulinic acid derivatives as anti-HIV matrices
US8846647B2 (en) * 2011-01-31 2014-09-30 Bristol-Myers Squibb Company C-17 and C-3 modified triterpenoids with HIV maturation inhibitory activity
BR112014014046A2 (pt) * 2011-12-14 2017-06-13 Glaxosmithkline Llc composto, composição, e, método para tratar hiv
US8906889B2 (en) * 2012-02-15 2014-12-09 Bristol-Myers Squibb Company C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
US8889854B2 (en) 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
CA2894126A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US9378035B2 (en) 2012-12-28 2016-06-28 Commvault Systems, Inc. Systems and methods for repurposing virtual machines
JP6186010B2 (ja) * 2013-02-06 2017-08-23 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Hiv成熟阻害活性を有するc−19修飾トリテルペノイド類
KR20150121712A (ko) * 2013-02-25 2015-10-29 브리스톨-마이어스 스큅 컴퍼니 Hiv의 치료에 유용한 c-3 알킬 및 알케닐 개질된 베툴린산 유도체
CN104877015B (zh) * 2014-02-28 2019-02-01 中国人民解放军军事医学科学院毒物药物研究所 一种三萜-多肽缀合物、其药物组合物及用途
UY36070A (es) 2014-04-11 2015-10-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Triterpenoides con actividad inhibidora de la maduración de hiv
MA40886B1 (fr) 2015-02-09 2020-03-31 Hetero Research Foundation Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih
PL3411358T3 (pl) 2016-02-04 2022-02-28 Takeda Pharmaceutical Company Limited Podstawiony związek piperydynowy i jego zastosowanie
AR107512A1 (es) * 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1

Also Published As

Publication number Publication date
NZ744545A (en) 2025-03-28
KR20180105229A (ko) 2018-09-27
RS61746B1 (sr) 2021-05-31
EP3411381B1 (en) 2021-01-20
CN109153700B (zh) 2021-03-09
MX2018009514A (es) 2018-09-05
JP2019504104A (ja) 2019-02-14
MY199668A (en) 2023-11-15
RU2018130181A (ru) 2020-03-05
UA123867C2 (uk) 2021-06-16
SG11201806388XA (en) 2018-08-30
EP3831839B1 (en) 2023-07-26
SMT202100210T1 (it) 2021-05-07
EA201891649A1 (ru) 2019-02-28
IL260741B (en) 2020-04-30
US20190031709A1 (en) 2019-01-31
BR112018015629B1 (pt) 2023-10-24
CO2018008157A2 (es) 2018-08-21
ZA201805044B (en) 2020-08-26
BR112018015629A2 (pt) 2018-12-26
AR107512A1 (es) 2018-05-09
TW201739757A (zh) 2017-11-16
TWI719126B (zh) 2021-02-21
RU2716502C2 (ru) 2020-03-12
PL3411381T3 (pl) 2021-09-13
PT3411381T (pt) 2021-03-18
MD3411381T2 (ro) 2021-07-31
KR102795662B1 (ko) 2025-04-14
US11084845B2 (en) 2021-08-10
RU2018130181A3 (enExample) 2020-03-05
ES2862325T3 (es) 2021-10-07
MA53358A (fr) 2021-07-21
CY1124353T1 (el) 2022-07-22
LT3411381T (lt) 2021-04-26
AU2017215529B2 (en) 2019-01-31
DOP2018000174A (es) 2018-10-31
CR20180387A (es) 2018-09-20
UY37109A (es) 2017-09-29
AU2017215529A1 (en) 2018-08-23
EP3831839A3 (en) 2021-07-21
US20210323997A1 (en) 2021-10-21
US10421774B2 (en) 2019-09-24
EP3831839A2 (en) 2021-06-09
MA43960A (fr) 2018-12-12
EP3411381A1 (en) 2018-12-12
HRP20210502T1 (hr) 2021-05-14
HUE054337T2 (hu) 2021-08-30
CA3013417C (en) 2024-01-02
JP6735837B2 (ja) 2020-08-05
SI3411381T1 (sl) 2021-04-30
PE20181355A1 (es) 2018-08-22
US20190359647A1 (en) 2019-11-28
CN109153700A (zh) 2019-01-04
MX375118B (es) 2025-03-06
ES2957767T3 (es) 2024-01-25
EA036211B1 (ru) 2020-10-14
WO2017134596A1 (en) 2017-08-10
US20230295220A1 (en) 2023-09-21
CA3013417A1 (en) 2017-08-10
CL2018002084A1 (es) 2018-09-21
HK1256866A1 (en) 2019-10-04
JOP20170029B1 (ar) 2021-08-17
DK3411381T3 (da) 2021-04-06
AU2017215529A8 (en) 2018-08-30

Similar Documents

Publication Publication Date Title
MA43960B1 (fr) Triterpénoïdes modifiés en c-3 et c-17 utilisés comme inhibiteurs du vih-1
MA34909B1 (fr) Triterpénoïdes modifi2s en c-17 et c-3 presentant une activité inhibitrice de la maturation du vih
JOP20220267A1 (ar) مركبات أمينو ثيازول تحمل بدائل بصفتها مثبطات لـثنائي أسيل غليسرول كيناز زيتا لتنشيط المناعة
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA39985B1 (fr) 1h-pyrrolo [2,3-c]pyridine -7(6h)-ones et pyrazolo[3,4-c]pyridine-7(6h)-ones en tant qu'inhibiteurs de protéines bet
MA34400B1 (fr) Dérivés d'acide 2-quinolinyl-acétique en tant que composés antiviraux contre le vih
MA39317A1 (fr) Dérivés de nucléosides à substitution 4'-difluorométhyle utilisés en tant qu'inhibiteurs de la réplication de l'arn du virus de la grippe
MA40886B1 (fr) Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih
MA44674B1 (fr) Inhibiteurs de bromodomaine
MA40225B1 (fr) Composés dihydroisoquinolinone substitués
MA38483A1 (fr) Inhibiteurs de l'ido
WO2019035864A8 (en) PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF BLOOD DISORDERS
MA40955A (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
MA34170B1 (fr) Inhibiteurs de transcriptase inverse non nucléosidiques
MA38182A1 (fr) Compositions pharmaceutiques a action prolongée pur une utilisation dans le traitement ou la prévention d'infections par le virus de l’immunodéficience humaine (vih)
EA202192433A1 (ru) Соединения, полезные в терапии вич
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
MA39374A1 (fr) Triterpénoïdes présentant une activité d'inhibition de la maturation du vih, substitués en 3ème position par un cycle non aromatique portant un substituant halogénoalkyle
MA40768A (fr) Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
MA41185B1 (fr) Composés d'acide isoxazole hydroxamique comme inhibiteurs de lpxc
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
MA40149A1 (fr) Dérivés de nucléoside 4'-vinyle substitués utiles en tant qu'inhibiteurs de la réplication due l'arn du virus respiratoire syncytial
MA38678A1 (fr) Dérivés nucléosidiques 4'-azido, 3'désoxy-3'-fluoro substitués
MA39253A1 (fr) Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr
MA46563B1 (fr) Compositions dispersibles